Drug Trial Radar · NCT07098403
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
Sep 3, 2025
Primary completion
Jan 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase III study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.
Conditions
- Asthma
Interventions
SHR-1905 InjectionDrug
SHR-1905 injection.
SHR-1905 Placebo InjectionDrug
SHR-1905 placebo Injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual asthma exacerbation rateTime frame: During 48 weeks of treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.